Emem medium

Ishikawa and MFE-280, respectively, well and poorly differentiated type I cell lines, were purchased from Sigma Aldrich (Milan, Italy). Ishikawa cells were grown in EMEM medium (Lonza, Milan, Italy), supplemented with 5% fetal bovine serum (FBS), 2 mM/L of glutamine, 100 IU/ml of penicillin, and 100 mg of streptomycin. MFE-280 cells were grown in EMEM medium (Lonza, Milan, Italy), supplemented with 10% FBS, 2 mM/L of glutamine, 100 IU/ml of penicillin, and 100 mg of streptomycin. HEC-1A and the primary EC cell lines PCEM002, PCEM004a, and PCEM004b were established in the lab of Frédéric Amant (Department of Oncology, KU Leuven, Leuven, Belgium). HEC-1A moderately differentiated type I cells were grown in Mc Coy’s medium (Lonza, Milan, Italy), supplemented with 10% FBS, 100 IU/ml of penicillin, and 100 mg of streptomycin, while the primary cell lines were grown in RPMI1640, supplemented with 20% FBS, 2 mM/L of glutamine, 100 IU/ml of penicillin, and 100 mg of streptomycin. PCEM002 is a poorly differentiated type I cell line, while PCEM004a and PCEM004b are poorly differentiated mixed type I/II cell lines. Media were changed every 48 h until cells were 90% confluent. All cell lines were maintained at 37°C with 5% CO₂ and 95% humidity.

Ishikawa and MFE-280 cells, respectively well and poorly differentiated type I cell lines, were purchased from Sigma-Aldrich (Milan, Italy). Ishikawa cells were grown in EMEM medium (Lonza, Milan, Italy), supplemented with 5% fetal bovine serum (FBS), 2 mM/L glutamine, 100 IU/mL penicillin, 100 mg streptomycin. MFE-280 cells were grown in EMEM medium (Lonza, Milan, Italy), supplemented with 10% fetal bovine serum (FBS), 2 mM/L glutamine, 100 IU/mL penicillin, 100 mg streptomycin. HEC-1A and the primary endometrial cancer cell lines PCEM002, PCEM004a, PCEM004b were kindly provided by Dr. Fréderic Amant (Department of Oncology, KU Leuven, Leuven, Belgium). HEC-1A moderately differentiated type I cells were grown in McCoy’s Medium (Lonza, Milan, Italy), supplemented with 10% FBS, 100 IU/mL penicillin, 100 mg streptomycin, while all the primary cell lines were grown in RPMI1640, supplemented with 20% FBS, 2 mM/L glutamine, 100 IU/mL penicillin, 100 mg streptomycin. PCEM002 is a poorly differentiated type I cell line while PCEM004a and PCEM004b are poorly differentiated mixed type I/II cell lines. All cell lines were maintained at 37 °C with 5% CO₂ and 95% humidity.

COS7 cell line was grown in a high glucose DMEM medium with L-Glutamine (Lonza) supplemented with 10% fetal bovine serum (Sigma) and 1% antibiotic/antimycotic (Sigma). Control fibroblast line (C0603, CGG^norm/-) and two fibroblast lines obtained from FXTAS patients, FX11-02 with one mutant and one normal allele (CGG^norm/CGG^exp) and WC26 with two mutant alleles (CGG^exp/CGG^exp) were a kind gift from A. Bhattacharyya (see also Rovozzo et al., 2016 (link)). Fibroblast cell lines were grown in EMEM medium (Lonza) supplemented with 15% fetal bovine serum (Sigma), 1% MEM non-essential amino acids (Thermo Fisher Scientific) and 1% antibiotic/antimycotic (Sigma). All cell lines were grown at 37°C in a humidified incubator containing 5% CO₂.